- Home
- CRK vs AKRO Comparison
CRK vs AKRO Comparison
Compare CRK & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRK
- AKRO
- Stock Information
- Founded
- CRK 1983
- AKRO 2017
- Country
- CRK United States
- AKRO United States
- Employees
- CRK N/A
- AKRO N/A
- Industry
- CRK Oil & Gas Production
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- CRK Energy
- AKRO Health Care
- Exchange
- CRK Nasdaq
- AKRO Nasdaq
- Market Cap
- CRK 4.8B
- AKRO 3.9B
- IPO Year
- CRK N/A
- AKRO 2019
- Fundamental
- Price
- CRK $15.94
- AKRO $49.38
- Analyst Decision
- CRK Hold
- AKRO Strong Buy
- Analyst Count
- CRK 9
- AKRO 7
- Target Price
- CRK $21.00
- AKRO $81.57
- AVG Volume (30 Days)
- CRK 2.6M
- AKRO 1.1M
- Earning Date
- CRK 07-30-2025
- AKRO 08-08-2025
- Dividend Yield
- CRK N/A
- AKRO N/A
- EPS Growth
- CRK N/A
- AKRO N/A
- EPS
- CRK N/A
- AKRO N/A
- Revenue
- CRK $1,654,969,000.00
- AKRO N/A
- Revenue This Year
- CRK $48.59
- AKRO N/A
- Revenue Next Year
- CRK $21.62
- AKRO N/A
- P/E Ratio
- CRK N/A
- AKRO N/A
- Revenue Growth
- CRK 20.80
- AKRO N/A
- 52 Week Low
- CRK $9.09
- AKRO $21.34
- 52 Week High
- CRK $31.17
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- CRK 25.27
- AKRO 47.31
- Support Level
- CRK $15.28
- AKRO $47.10
- Resistance Level
- CRK $16.55
- AKRO $50.19
- Average True Range (ATR)
- CRK 0.76
- AKRO 2.36
- MACD
- CRK -0.00
- AKRO 0.02
- Stochastic Oscillator
- CRK 10.84
- AKRO 51.14
About CRK Comstock Resources Inc.
Comstock Resources Inc is an independent natural gas producer operating in the Haynesville shale, a natural gas basin located in North Louisiana and East Texas with superior economics given its geographical proximity to the Gulf Coast natural gas markets. The Company operates in one business segment, the exploration and production of North American natural gas and oil. It is engaged in the acquisition, development, production, and exploration of oil and natural gas. Its oil and gas operations are concentrated in Louisiana and Texas.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.